Optimizing Therapy News Today

Marcia Brose, MD, examines data from the COSMIC-311 study, emphasizing the importance of promptly initiating second-line therapy for patients who have progressed on first-line treatments.

Daniel Bowles, MD, discusses the toxicity profiles and adverse reactions associated with frontline and second-line treatments for differentiated thyroid cancer (DTC).

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

Francis Worden, MD, analyzes the outcomes of the SELECT and DECISION Trials, focusing on progression-free survival, and provides recommendations for their application in clinical practice.

Daniel Bowles, MD, leads a discussion on radioactive iodine (RAI) refractory disease, exploring the incidence and resistance levels, and provides recommendations for identifying patient populations who are ineligible for radioiodine treatment.

Medical professionals discuss the role of thyroidectomy and nodal disease in leading to surgery, providing an overview of the various surgical treatment options available for differentiated thyroid cancer.

The panel discusses the importance of thyroid hormone replacement and TSH suppression, highlighting the role of endocrinologists in managing the risk of cardiovascular disease. Dr. Brose also addresses the potential long-term risks associated with radioactive iodine treatment in the post-surgery setting, including cytopenia, salivary gland issues, and excessive tearing of the eyes.

Daniel Bowles, MD, explores the role of molecular testing in driving treatment decisions and its application in the initial diagnosis stage, while also discussing driver mutations, primary surgeries, and the importance of high-quality DNA and RNA, highlighting the 2-year window for durable RNA sequencing.

Francis Worden, MD, and Hyunseok Kang, MD, express caution regarding the use of liquid biopsies due to discordant findings and the potential lack of tumor shedding compared to other solid tumors, while also warning about the misinterpretation of Clonal hematopoiesis of indeterminate potential mutations.